Enveric Biosciences, Inc. · NASDAQ:ENVB
Enveric Biosciences — Investor Presentation (January 2025)
15 slides from Enveric Biosciences's investor presentation, Jan 3, 2025
Slide 1: Corporate Presentation Q1 2025
! Nasdaq:ENVB Ey A ENVERIC ™ wenrnecin BrI°O-S<C ISBN CE S CORPORATE PRESENTATION Q12025 Enveric.com
Slide 2: Disclaimer
Disclaimer
Slide 3: Slide 3
Slide 4: Significant Global Health Issues: Depression, Anxiety & PTSD
Significant Global Health Issues: Depression, Anxiety & PTSD 65 million in the US ey) 40% 1 billion globally Experience a neuropsychiatric First line SSRI treatments work disorder at some time in their lives for less than half of patients Recent Discovery: Mental health disorders are associated with
Slide 5: Neuroplastogens: A New Class of Drugs
Neuroplastogens: A New Class of Drugs Prefrontal Cortex Healthy Brain: Neurons in the prefrontal cortex (PFC) regulate emotional behavior via Top-Down control of the amygdala. This modulates the fight-or-flight thoughts and emotions that originate in the amygdala) Neuroplastogens stimulate neuroplas
Slide 6: Psychedelic Neuroplastogen Drawbacks
Psychedelic Neuroplastogen Drawbacks: + Current neuroplastogens in clinical trials cause hallucinations in the patient + Require 8 hrs in-clinic treatment with two healthcare providers present, plus pre and post treatment ‘counselling + Require psychotherapy as part of the treatment paradigm + Expen
Slide 7: EB-003: Non-Hallucinogenic Neuroplastogen Discovered in 1,000+ Molecule Library
EB-003: Non-Hallucinogenic moh Wt Neuroplastogen Discovered in N Q 1,000+ Molecule Library NH2 we d biol id y “ + Integrated synthetic biology an g y gy F N f N chemistry to create new library + Designed molecules based on NO natural serotonin receptor ligands HO. N FE. A / a oh™ + Screened for appr
Slide 8: EB-003: A New Treatment Standard
EB-003: A New Treatment Standard Approved Psychedelic Targeted Benefits” Antidepressants Neuroplastogens For EB-003 Immediate efficacy v v Low side effects v Treatment in-clinic not required v v Large patient population Vv Vv Induces neuroplasticity in brain Vv Vv *To be proven in human clinical tri
Slide 9: EB-003: Development Underway
EB-003: Development Underway Synopsis of Target Benefits + Reduced hallucination profile, treatment in clinic not required + Lower side effects + Rapid acting + Orally bioavailable + Intended to be prescribed for regular maintenance and taken at times and in settings convenient to patient i PRECLINI
Slide 10: Market Potential: Redefining the Treatment Landscape for Mental Health Disorders
Market Potential: Redefining the Treatment Landscape for Mental Health Disorders Predicted Neuroplastogen Current Approved Antidepressant Market: EB-003: A Breakthrough Market: 3% Neuroplastogen = Global market driven by the rising (v) EB-003 could be one of the first Low side-effects, strong effica
Slide 11: Additional Assets Leveraged from Discovery Platform
Additional Assets Leveraged from Discovery Platform * Portfolio of 1000+ novel drug candidates * 23 issued patents & 60 pending patent applications + Numerous distinct assets available for partnering or out- licensing + Multiple future revenue streams possible PA nasdaq @sdaq:ENVB
Slide 12: Discovery to Partner/Licensee pipeline
Discovery Pre-Clinical IND Phase1 Partner/ Licensee Partner Available Licensee EB-002 & EVM201 MycoMedica Life Sciences Topical Product for Radiation Damme Arles Science & Technology PA vasdag:enve a
Slide 13: Management
Management Management Team Joseph Tucker, Ph.D. c itive Officer Chief Exe Kevin Coveney, CPA Chief Fin PA nasda NVB Board of Directors Michael D. Webb Board Chair George Kegler Director, Chair of the Audit Committee Frank Pasqualone Director, Chair of the Compensation and Nominating Committees Marcu
Slide 14: Potential First in Class Entrant to Large Mental Health Market
Potential First in Class Entrant to Large Mental Health Market EB-003: A Paradigm Shifting Drug Candidate + EB-003 is one of the leading neuroplastogen drug candidates + Anticipate filing IND in Ql of 2026 and Phase | start in Q2 2026 New Drug Class Market Opportunity + A$35. billion market awaits:
Slide 15: Next Generation Mental Health
| VY | e Next Generation € € Mental Health™ Cc E Enveric.com DO
Enveric Biosciences — Investor Presentation (January 2025) on 6ix